Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:STTK

Shattuck Labs Q3 2025 Earnings Report

Shattuck Labs logo
$6.71 +0.17 (+2.60%)
As of 03:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Shattuck Labs EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Shattuck Labs Revenue Results

Actual Revenue
$1.00 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Shattuck Labs Announcement Details

Quarter
Q3 2025
Date
11/6/2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Shattuck Labs' Q1 2026 earnings is estimated for Thursday, May 7, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Shattuck Labs' Q3 2025 Earnings ReleaseEarnings Release
(8-K)
Shattuck Labs' Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

Shattuck Labs Earnings Headlines

Cantor Fitzgerald Initiates Coverage of Shattuck Labs (STTK)
May 1, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/cantor-fitzgerald-initiates-coverage-of-shattuck-labs-sttk-1750621/
Shattuck Labs (STTK) price target increased by 24.00% to 12.65
April 29, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/shattuck-labs-sttk-price-target-increased-by-24-00-to-12-65/ar-AA21WpxL
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 6 at 1:00 AM  |  American Alternative (Ad)
Cantor Fitzgerald initiates coverage of Shattuck Labs (STTK) with overweight recommendation
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/cantor-fitzgerald-initiates-coverage-of-shattuck-labs-sttk-with-overweight-recommendation/ar-AA21Tg4i
Shattuck Labs: Surviving In An AI World Is Going To Be Tough
March 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4886562-shutterstock-surviving-in-an-ai-world-is-going-to-be-tough
Shattuck Labs (STTK) price target increased by 37.93% to 10.20
March 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/shattuck-labs-sttk-price-target-increased-by-37-93-to-10-20/ar-AA1ZvVtR
See More Shattuck Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shattuck Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shattuck Labs and other key companies, straight to your email.

About Shattuck Labs

Shattuck Labs (NASDAQ:STTK) (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities. Preclinical studies have demonstrated that vaccinated animals produce robust anti‐fentanyl antibody titers and are protected against lethal and sublethal fentanyl challenges. Shattuck Labs is advancing its vaccine candidate through IND‐enabling studies and plans to initiate first‐in‐human trials to evaluate safety, immunogenicity, and its potential to block the psychoactive effects of fentanyl.

Founded in 2017, Shattuck Labs was established to address the growing public health crisis posed by opioid misuse and overdose. The company leverages insights from immunology and vaccinology, collaborating with academic partners and contract manufacturing organizations to streamline development and scale up production. Shattuck Labs serves the U.S. market and is preparing for broader geographic reach as its clinical programs progress.

Shattuck Labs is led by Chief Executive Officer Craig H. Wheeler, who brings extensive experience in biopharmaceutical R&D and commercial strategy. The management team includes experts in vaccine formulation, regulatory affairs, and translational medicine. Through its focused pipeline and innovative platform, Shattuck Labs aims to pioneer a new class of non‐addictive, immunotherapeutic treatments for substance use disorders.

View Shattuck Labs Profile
Earnings Tools